Ocugen Inc OCGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OCGN is a good fit for your portfolio.
News
-
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGN
-
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ocugen, QuidelOrtho, and Sharecare and Encourages Investors to Contact the Firm
-
IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
-
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen
-
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGN
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ocugen, and QuidelOrtho and Encourages Investors to Contact the Firm
-
OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ocugen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Trading Information
- Previous Close Price
- $1.18
- Day Range
- $1.12–1.20
- 52-Week Range
- $0.35–2.11
- Bid/Ask
- $1.19 / $1.20
- Market Cap
- $302.36 Mil
- Volume/Avg
- 2.1 Mil / 10.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 50.19
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 84
- Website
- https://www.ocugen.com
Comparables
Valuation
|
Metric
|
OCGN
|
AVIR
|
TGTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 17.99 |
Price/Book Value | 7.84 | 0.56 | 13.44 |
Price/Sales | 50.19 | — | 9.06 |
Price/Cash Flow | — | — | 39.74 |
Price/Earnings
OCGN
AVIR
TGTX
Financial Strength
|
Metric
|
OCGN
|
AVIR
|
TGTX
|
|---|---|---|---|
Quick Ratio | 2.31 | 17.86 | 5.00 |
Current Ratio | 2.51 | 18.24 | 5.92 |
Interest Coverage | — | — | 2.04 |
Quick Ratio
OCGN
AVIR
TGTX
Profitability
|
Metric
|
OCGN
|
AVIR
|
TGTX
|
|---|---|---|---|
Return on Assets (Normalized) | −57.05% | −15.46% | 19.44% |
Return on Equity (Normalized) | −77.46% | −16.16% | 54.76% |
Return on Invested Capital (Normalized) | −70.27% | −19.92% | 35.76% |
Return on Assets
OCGN
AVIR
TGTX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cgqtxwjvv | Hdry | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fkfzbthyg | Vkkjznk | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zfqtcjnr | Pdbgrd | $99.5 Bil | |
MRNA
| Moderna Inc | Ffjyhygs | Dkj | $38.8 Bil | |
ARGX
| argenx SE ADR | Lwvfmyhc | Bqs | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Nlcdclwk | Zxc | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lzczjxqq | Sdxcm | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wdmhqcmp | Ptvbdmq | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qzxqtblcj | Nwjxw | $12.5 Bil | |
INCY
| Incyte Corp | Lqlrdwc | Bthpwh | $11.6 Bil |